taVNS for Speech and Language Recovery in Aphasia
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: taVNS, sham taVNS.
- Who it may be relevant to
- Registry conditions: Aphasia, Apraxia of Speech. Basic parameters: 18 years — 80 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- United States
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Non-invasive Vagus Nerve Stimulation for Language Recovery in Aphasia
Overview
The goal of this research study is to evaluate a novel approach to improving speech recovery in those with acquired apraxia of speech. We will enroll participants with apraxia of speech resulting from stroke or brain injury to complete several tasks and intervention. Testing will take place four times over the course of the study and intervention will take place 5 days a week for 16 weeks. Overall, you can expect to spend up to 17 weeks participating in this study.
Interventions
- Device taVNS
active vagus nerve stimulation - Device sham taVNS
sham vagus nerve stimulation
Primary outcome measures
- Adverse events [Time frame: 6 months]
- Compliance [Time frame: 6 months]
Secondary outcome measures (1)
- Change in speech production scores [Time frame: 6 months]
Eligibility criteria
Inclusion criteria
- Adults between 18-80
- Native speakers of English or simultaneous bilinguals
- At least 6 months post stroke or TBI
- Diagnosed production type aphasia or apraxia of speech
Exclusion criteria
- Additional cognitive or neurological impairments (Autism, schizophrenia, seizures, etc)
- Language comprehension deficits
- Medications that influence key neurotransmitters
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Double blind
- Primary purpose
- Treatment
Study locations
United States · 1 center
- Brooks Rehabilitation Clinical Research Center — Jacksonville
Identifiers
NCT: NCT07563387 · IRB202501105